it involves a non contractual agreement between the uk department of health and the association of the british pharmaceutical industry abpi the scheme applies to all branded licensed medicines available on the nhs the purpose of the scheme is to achieve a balance between reasonable prices for the nhs and a fair return for the pharmaceutical industry the current pprs scheme using a value based pricing mechanism came into effect on 1 january 2014 to run for no less than five years it replaced an earlier scheme running from 2009 to 2013 in december 2014 hoffmann la roche successfully appealed against a decision of the national institute for health and care excellence appraisal committee in respect of kadcyla on the basis that it should have considered that under the scheme the industry had agreed to cap growth in the drugs bill to 0 1 9 a year for the next five years roche said this had fundamentally changed the nature of how nice should consider cost effectiveness on 23 august 2017 the uk government launched a consultation relating to the pprs following legislation that was recently passed as the primary buyer of medicines in the uk the department of health